Triple-negative breast cancer (TNBC) is a breast cancer subtype that lacks expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2), with a diagnosis rate of 15–20% in breast cancer patients1–3. This evidence concerns the gene ERBB2 and breast cancer.